Skip to main content
. 2023 Jul 23;8(4):101613. doi: 10.1016/j.esmoop.2023.101613

Figure 2.

Figure 2

(A) Overall incidence of interstitial lung disease (ILD) (all grades) and ILD stratified by study type. (B) Subgroup analysis according to administered dosing of trastuzumab deruxtecan (T-DXd) revealed a significantly higher rate of ILD for 6.4 mg/kg compared to 5.4 mg/kg (22.7% versus 10.2%; P < 0.01). CI, confidence interval.